CA2614526A1 - Formulation de benzimidazole - Google Patents
Formulation de benzimidazole Download PDFInfo
- Publication number
- CA2614526A1 CA2614526A1 CA002614526A CA2614526A CA2614526A1 CA 2614526 A1 CA2614526 A1 CA 2614526A1 CA 002614526 A CA002614526 A CA 002614526A CA 2614526 A CA2614526 A CA 2614526A CA 2614526 A1 CA2614526 A1 CA 2614526A1
- Authority
- CA
- Canada
- Prior art keywords
- alkaline substance
- dry
- benzimidazole
- alkaline
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200501019 | 2005-07-11 | ||
DKPA200501019 | 2005-07-11 | ||
US72785505P | 2005-10-19 | 2005-10-19 | |
US60/727,855 | 2005-10-19 | ||
PCT/DK2006/000409 WO2006105798A2 (fr) | 2005-07-11 | 2006-07-11 | Formulation de benzimidazole |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2614526A1 true CA2614526A1 (fr) | 2006-10-12 |
Family
ID=37492042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002614526A Abandoned CA2614526A1 (fr) | 2005-07-11 | 2006-07-11 | Formulation de benzimidazole |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1901719A2 (fr) |
AU (1) | AU2006230974C1 (fr) |
CA (1) | CA2614526A1 (fr) |
EA (1) | EA015535B1 (fr) |
WO (1) | WO2006105798A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5228359B2 (ja) * | 2007-04-12 | 2013-07-03 | ニプロ株式会社 | 主薬粒子及びその製造方法ならびに口腔内崩壊錠 |
TWI441658B (zh) | 2008-03-11 | 2014-06-21 | Takeda Pharmaceutical | 口腔崩解固體製劑 |
TR201000948A1 (tr) * | 2010-02-09 | 2011-08-22 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Aripiprazol formülasyonları. |
WO2012166899A2 (fr) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib |
CN103479593B (zh) * | 2013-05-10 | 2014-10-08 | 青岛双鲸药业有限公司 | 一种奥美拉唑肠溶片的制备方法 |
CN103386133A (zh) * | 2013-07-09 | 2013-11-13 | 重庆莱美药业股份有限公司 | 一种质子泵抑制剂的口腔速溶制剂及其制备方法 |
RS63559B1 (sr) | 2014-08-28 | 2022-10-31 | Eisai R&D Man Co Ltd | Derivat hinolina velike čistoće i postupak za njegovu proizvodnju |
PL3263106T3 (pl) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Sposób tłumienia goryczy pochodnej chinoliny |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
CN104825414B (zh) * | 2015-05-07 | 2018-11-16 | 山东新时代药业有限公司 | 一种稳定的s-泮托拉唑钠肠溶片 |
BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
CN113318079B (zh) * | 2021-05-13 | 2024-01-09 | 江西博莱大药厂有限公司 | 一种提高三氯苯达唑颗粒溶出度的方法及其溶出度检测方法 |
CN115645373B (zh) * | 2022-12-24 | 2024-01-30 | 山东理工职业学院 | 一种奥美拉唑钠片的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5433959A (en) * | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
JP2001524131A (ja) * | 1997-05-09 | 2001-11-27 | セイジ、ファーマスーティカルズ、インク | 安定な経口医薬品剤形 |
US20020039597A1 (en) * | 1998-04-20 | 2002-04-04 | Koji Ukai | Stabilized compositions containing benzimidazole-type compounds |
US20020064555A1 (en) * | 2000-09-29 | 2002-05-30 | Dan Cullen | Proton pump inhibitor formulation |
AR036354A1 (es) * | 2001-08-31 | 2004-09-01 | Takeda Chemical Industries Ltd | Preparacion solida |
CA2517289A1 (fr) * | 2003-02-28 | 2004-09-10 | Ranbaxy Laboratories Limited | Compositions pharmaceutiques stables de rabeprazole et leurs procedes de fabrication |
CA2529984C (fr) * | 2003-06-26 | 2012-09-25 | Isa Odidi | Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif |
MXPA06000577A (es) * | 2003-07-17 | 2006-07-03 | Reddy S Lab Ltd | Composiciones farmaceuticas que tienen un recubrimiento hinchable. |
-
2006
- 2006-07-11 EP EP06753346A patent/EP1901719A2/fr not_active Withdrawn
- 2006-07-11 AU AU2006230974A patent/AU2006230974C1/en not_active Ceased
- 2006-07-11 EA EA200800290A patent/EA015535B1/ru not_active IP Right Cessation
- 2006-07-11 CA CA002614526A patent/CA2614526A1/fr not_active Abandoned
- 2006-07-11 WO PCT/DK2006/000409 patent/WO2006105798A2/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2006230974C1 (en) | 2012-02-02 |
WO2006105798A3 (fr) | 2006-12-07 |
EA015535B1 (ru) | 2011-08-30 |
EP1901719A2 (fr) | 2008-03-26 |
AU2006230974A1 (en) | 2006-10-12 |
AU2006230974B2 (en) | 2011-09-29 |
EA200800290A1 (ru) | 2008-08-29 |
WO2006105798A2 (fr) | 2006-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006230974C1 (en) | Benzimidazole formulation | |
JP6934932B2 (ja) | アンドロゲン受容体アンタゴニストの固体医薬組成物 | |
JP2016164170A (ja) | プロトンポンプ阻害剤を含む制御放出組成物 | |
JP7482182B2 (ja) | プロトンポンプ阻害剤を含む経口用固形製剤組成物、それを含む経口用固形製剤及びその製造方法 | |
WO2011140446A2 (fr) | Formulations pharmaceutiques | |
WO2012018056A1 (fr) | Composition comprimée | |
MX2014007331A (es) | Sistema de multiunidades de granulos de liberacion inmediata. | |
US20070020334A1 (en) | Benzimidazole formulation | |
AU2018203007B2 (en) | Ceritinib formulation | |
Sun et al. | A microcrystalline cellulose based drug-composite formulation strategy for developing low dose drug tablets | |
CA2905423A1 (fr) | Comprimes de sovaprevir | |
EP1909761B1 (fr) | Préparation pharmaceutique comprenant du pantoprazole granulaire | |
WO2021074808A1 (fr) | Composition pharmaceutique comprenant du sacubitril et du valsartan et son procédé de préparation | |
KR101845665B1 (ko) | 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법 | |
US20100055177A1 (en) | Modified release composition of levetiracetam and process for the preparation thereof | |
WO2008015530A2 (fr) | Formulation orale solide stable d'un medicament acide labile | |
JP2021518423A (ja) | レナリドミドの経口用コーティング錠剤組成物 | |
AGIBA et al. | Modulatory effect of polymer type and concentration on drug release from sustained release matrix tablets of ranolazine: a comparative release kinetic study | |
Ray et al. | Formulation and evaluation of once daily sustained release matrix tablet of verapamil hydrochloride | |
JP2018030810A (ja) | ゲフィチニブを有効成分とする医薬錠剤の製造方法 | |
JP2024003789A (ja) | 時限放出型顆粒およびその用途 | |
KR20180060174A (ko) | 덱스란소프라졸을 포함하는 경구용 정제 조성물, 이를 포함하는 경구용 정제 및 그 제조방법 | |
Naiserová et al. | perorálních tablet | |
GB2334212A (en) | Modified release matrix formulation for cefaclor and cephalexin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |
Effective date: 20151217 |